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13.1 Introduction
Malaria threatens 40% of the world’s population and kills 1–3 million humans,
mostly children under five, every year.1 The lack of effective vaccines and the
spreading of drug-resistant parasites has led to a resurgence of malaria in many
countries.2,3 It is therefore imperative that our understanding of the funda-
mental biology and biochemical processes at different stages of the life cycle
of the malaria parasite be improved, to facilitate the identification of new
targets for the development of novel drugs.
DNA replication represents one such key biochemical process of the parasite.
It takes place in at least five distinct points in the parasite life cycle, two of which
occur in the human host (i.e. exo-erythrocytic and erythrocytic schizogony in
liver and red blood cells, respectively); the remainder take place in the mosquito
host (i.e. gametogenesis in midgut, pre-meiosis after fertilisation and sporogony
in oocysts)4 (Figure 13.1). Thus the selective disruption of DNA synthesis in the
parasite might not only inhibit the disease itself but also block parasite trans-
mission by the mosquito vector. During gametogenesis, three successive rounds
of genome replication are completed within 10 minutes, raising the DNA content
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Figure 13.1 Plasmodium falciparum life cycle. The life cycle of the malarial parasite
involves two hosts: mosquito and human. It may be divided into three
stages. One is sexual and takes place inside the mosquito, while the other
two are asexual and occur inside the human host: the erythrocytic cycle
(in red blood cells) and the exo-erythrocytic cycle (in liver cells). During a
blood meal, a malaria-infected female Anopheles mosquito inoculates
sporozoites into the human host. Sporozoites, upon entering the blood-
stream, will reach the liver (hepatocytes) where they mature into schizonts,
which rupture and release merozoites. After this initial replication in the
liver (exo-erythrocytic schizogony), the parasites undergo asexual multi-
plication in red blood cells (erythrocytic schizogony). Merozoites infect
erythrocytes becoming ring-forms. The ring-forms progress to tropho-
zoites and mature into schizonts. The segmented schizonts rupture
releasing merozoites. Some parasites in red blood cells differentiate into
sexual erythrocytic stages (gametocytes). The gametocytes, including male
(microgametocytes) and female (macrogametocytes), are ingested by an
Anopheles mosquito during a blood meal. The microgametocytes undergo
exflagellation in the midgut generating microgametes. The microgametes
fertilise the macrogametes producing zygotes. The zygotes in turn become
motile and elongated to form ookinetes that invade the midgut wall of the
mosquito where they develop into oocysts. The oocysts grow, rupture and
release sporozoites, which migrate to the salivary glands. Inoculation of
the sporozoites by the mosquito into a new human host continues to
transmit the parasites.
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to octoploid values just before exflagellation, suggesting that the genome
duplication rate of the parasite is extremely high. Assuming that the rate of
replication fork movement in the parasite is similar to that in other eukaryotes, at
least 1300 replication origins among the 14 chromosomes of Plasmodium would
be needed to achieve this rate of replication.5 It is known that at least two
replication origins exist within each inverted repeat region of the 35kb apicoplast
genome of the parasite6–8 but information concerning replication origins on
nuclear chromosomes of the parasite remains absent.
This chapter focuses on the important molecules (Tables 13.1, 13.2 and 13.3)
involved in the DNA replication initiation and elongation processes, and
their potential as targets for development of novel drugs against Plasmodium
falciparum—the most malignant pathogen of four malarial parasite species that
infect humans.
13.2 Replication Initiation Proteins
13.2.1 PfORC
The initiation of DNA replication is tightly regulated such that all chromosomes
are replicated precisely at specific points in the parasite life cycle (Figure 13.1). In
eukaryotes, ORC is a multi-subunit protein complex composed of six polypep-
tides (ORC1-6) that binds to replication origins and is essential for the initiation
of chromosomal DNA replication (see Chapters 1 and 2). It was originally
thought that only two or three PfORC homologues exist in P. falciparum.9–11
However, extensive bioinformatics investigations reveal that there may be four
putative homologues (i.e. PfORC1, 2, 4 and 5) in the parasite genome.
PfORC1 was the first malarial ORC isolated from P. falciparum using vec-
torette technology.12 PfORC1 is composed of two distinct domains: a variable
N-terminal domain (residue positions 1–783) and a highly conserved C-term-
inal domain (residue positions 784–1189). The N-terminal domain is the largest
extension in the ORC1 family and contains several other unique characteristics:
(i) It is rich in serine/threonine and tyrosine (20%), forming a number of
potential phosphorylation sites for a range of known protein kinases
such as cyclin-dependent kinases, suggesting that PfORC1 may be
regulated by phosphorylation.
(ii) It contains a large proportion (30%) of charged amino acid residues
(K, R, E and D) that may be involved in protein–protein interactions.
(iii) It has four copies of a heptamer ISSSLT(S)N repeat.
(iv) It includes two putative nuclear localisation signal (NLS) motifs, sug-
gesting that PfORC1 may be a nuclear protein.
(v) It possesses a leucine zipper motif (LX6LX6LX6L) that may be involved
in DNA-binding activity.
The C-terminal domain of PfORC1 shares 48–61% similarity and 27–40%
identity with members of the ORC1 family from other species, and contains all
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conserved sequences of the family including the Walker A (GMPGTGKT,
815–822) and Walker B (DEID, 903–906) motifs of the classical purine
nucleotide-binding sites (see Chapter 2), suggestive of ATP binding and
hydrolysis activity of PfORC1 (Figure 13.2A). Indeed, ATPase activity of the
recombinant C-terminal domain has been recently confirmed in vitro and, like
other AAA1 ATPases, is dependent on the K821 residue within the Walker A
motif.10 In addition, PfORC1, like most members of the ORC1 family
from other species, contains a putative PCNA binding motif, QKVLFTLF
(913–920), suggestive of an interaction with PfPCNA (see Chapter 3). In fact,
PfORC1 has been shown to interact with PfPCNA1 in vitro and to co-localise
with the majority of the PfPCNA1 replication foci during trophozoite stages.9
Expression of PfORC1 has been demonstrated in the parasite nucleus during
late trophozoite and early schizont stages and in sexual stages,9,10,12–15 con-
sistent with its potential role in replication initiation in these stages. Recently, it
was reported that PfORC1 can specifically interact with telomeres and with
various subtelomeric repeats and, thus, act also as a telomere-associated pro-
tein in P. falciparum.15 More than 80% of PfORC1 nuclear foci were shown to
co-localise with PfSir2, a telomeric protein that was identified as reversibly
associating with the promoter regions of silent but not active subtelomeric
var genes.16,17 Therefore, PfORC1 may cooperate with PfSiv2 and contribute
to telomeric silencing of virulence-factor genes and antigenic variation in
P. falciparum by a phenomenon called the telomere position effect.18 Structural
modelling of PfORC1 against archeal ORC/cdc6 suggests very strong con-
servation such that plasmodium PfORC1 may similarly distort the helical axis
of DNA (Figure 13.2B), thought to be important for localised melting of the
origin during replication initiation (see also Figure 12.1).
PfORC2, like PfORC1, shares 45% similarity and 26% identity with human
ORC2 only at the C-terminal region (residue positions 488–825) (J-L. Li
unpublished data). PfORC2 is transcribed during late trophozoite and early
schizont stages,14,19 consistent with a role in DNA replication.
PfORC4 contains the Walker A (GMLGCGKT, 160–167) and Walker B
motifs (DEND, 270–273) characteristic of other ORC family members
and consistent with a proposed action as an AAA1 ATPase (see Chapter 2).
Figure 13.2 PfORC1. (A) The ORC1/Cdc6/Cdc18 domain. Sequences were aligned
with the CLUSTAL W (1.85) multiple sequence alignment program,71,72
using data from GenBank/EMBL/DDJB database accession numbers:
P. falciparum PfORC1, AF373219; human HsORC1, Q13415; and
human HsCdc6, U77949. Six conserved blocks that define PfORC1 as a
member of the ORC1/Cdc6/Cdc18 family are highlighted with grey and
labelled at the bottom of the sequence. A putative PCNA-binding motif
(913–920) is highlighted in black and underlined at the bottom of the
sequence. (B) Predicted structure of PfORC1. Molecular modelling of
PfORC1 (green) was conducted using SWISS-MODEL73,74 and Mac-
PyMOL (http://delsci.com/macpymol/) with archaeal ORC/Cdc6 (PDB
accession number 2QBY) (red in figure) as a template.
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                  10        20        30        40        50        60        70        80
----:----|----:----|----:----|----:----|----:----|----:----|----:----|----:----|
Consensus xExxxxLxxxxVPExLPxREKExxxIxxFLxxxIxxxxxxxxLYISGxPGTGKTAxVxxVIQxLQxxxRxxxxxxFxxxx
HsORC1    EEARLRLHVSAVPESLPCREQEFQDIYNFVESKLLDHTGG-CMYISGVPGTGKTATVHEVIRCLQQAAQANDVPPFQYIE
PfORC1    DKAIRMMQLDVVPKYLPCREKEIKEVHGFLESGIKQSGSNQILYISGMPGTGKTATVYSVIQLLQIKSRKKLLPSFNVFE
HsCdc6    YQQAKLVLNTAVPDRLPAREREMDVIRNFLREHICGKKAG-SLYLSGAPGTGKTACLSRILQDLKKELKG-----FKTIM
Block 1 (Walker A)
 90       100       110       120       130       140       150       160
----:----|----:----|----:----|----:----|----:----|----:----|----:----|----:----|
Consensus INxMxLxxxxxxYxxxxQQLxxQKxxSxxxxxELLxKxxxxxxxxxxxxxVLIIDELDxLxTxxQxVLYxLFDWPxxxxS
HsORC1    VNGMKLTEPHQVYVQILQKLTGQK-ATANHAAELLAKQFC-TRGSPQETTVLLVDELDLLWTHKQDIMYNLFDWPTHKEA
PfORC1    INGMNVVHPNAAYQVFYKQLFNKKPPNALNSFKIIDRLFNKSQKDNRDVSILIIDEIDYLITKTQKVLFTLFDWPTKINS
HsCdc6    LNCMSLRTAQAVFPAIAQEICQEE-VSRPAGKDMMRKLEKHMTAEKGPMIVLVLDEMDQLDSKGQDVLYTLFEWPWLSNS
Block 2   Block 3 (Walker B)
                 170       180       190       200       210       220       230       240
----:----|----:----|----:----|----:----|----:----|----:----|----:----|----:----|
Consensus xLVLIxIANTMDLxDRILxxRxxSRxxxxxxxLxFxPYxxNQIxxILRxRLxxxxxxxxxDNxAIQxxARKVAxVSGDxR
HsORC1    RLVVLAIANTMDLPERIMMNRVSSRLGLT--RMCFQPYTYSQLQQILRSRLKH--LKAFEDD-AIQLVARKVAALSGDAR
PfORC1    KLILIAISNTMDLPDRLIP-RCRSRLAFG--RLVFSPYKGDEIEKIIKERLEN--CKEIIDHTAIQLCARKVANVSGDIR
HsCdc6    HLVLIGIANTLDLTDRILP-RLQAREKCKPQLLNFPPYTRNQIVTILQDRLNQVSRDQVLDNAAVQFCARKVSAVSGDVR
Block 4                        Block 5                          Block 6
                 250       260       270       280       290       300       310       320
----:----|----:----|----:----|----:----|----:----|----:----|----:----|----:----|
Consensus KxLxICRRAxxxxxxxxxxxxxIxxxSxxxxxSxxxxPxxxxIxHxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxI
HsORC1    RCLDICRRAT-----------EICEFSQQKPDS----PGLVTIAHSMEAVDEMFSSSYITA-IKNSSVLEQSFLR---AI
PfORC1    KALQICRKAFENKRGHKIVPRDITEATNQLFDS----PLTNAINYLPWAFKIFLTCLIIELRIINEFVIPYKKVVNRYKI
HsCdc6    KALDVCRRAIEIVESDVKSQTILKPLSECKSPSEPLIPKRVGLIHISQVISEVDGNRMTLSQEGAQDSFPLQQKILVCSL
                 330       340       350       360       370       380       390       400
----:----|----:----|----:----|----:----|----:----|----:----|----:----|----:----|
Consensus LxxxxxxxxxxxxxxxLxExxxxKLxxxxxxLxRxxxIxxxxxSExxSxxxxLxxxxxxxxxxxxxxxxxxVxxxxNKxx
HsORC1    LAEFR--------RSGLEEATFQQIYSQHVALCRMEGLPYPTMSETMAVCSHLGSCR-----------LLLVEP--SRND
PfORC1    LIETSGKYIGMCSDNELFKIMLDKLVKMGILLIRPY-IPLENISKNKSKEALLGFNESSKKGNNQKITRAQVSPDIDKES
HsCdc6    MLLIR--------QLKIKEVTLGKLYEAYSKVCRKQQVAAVDQSECLSLSGLLEARG-------------ILGLKRNKET
                 410       420       430       440       450       460       470       480
----:----|----:----|----:----|----:----|----:----|----:----|----:----|----:----|
Consensus xxxxVxxxVxxxxIxxALxxExxxxxxxxxxxx
HsORC1    LLLRVRLNVSQDDVLYALKDE------------
PfORC1    GDMGIELNVETQLIITALMKDPDCSKKLNFY--
HsCdc6    RLTKVFFKIEEKEIEHALKDKALIGNILATGLP
A
B
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The central region (residues 431–660) of PfORC4 displays up to 31% identity
and 50% similarity with other members of ORC4 family. Oligonucleotide array
analysis showed that PfORC4 is expressed not only in trophozoite and early
schizont stages,19 but also in sexual and sporozoite stages.14
PfORC5, like PfORC1, comprises two distinct domains: a variable
N-terminal domain and a highly conserved C-terminal domain. The N-terminal
extension contains a putative NLS motif (residue positions 56–72) and a D/N/
K-rich repeat (residue positions 81–170). The C-terminal domain of PfORC5
exhibits 25% identity and 46% similarity (between the 572–815 region) with
Drosophila ORC5. PfORC5, like Saccharomyces cerevisiae ORC5 (ScORC5),
contains the ATP-binding motif (GLPGMGKT, 303–310) but lacks the
Walker B motif designated as a nucleotide hydrolysis domain (see Chapter 2).
Between the ATP-binding motif and the C-terminal conserved region, however,
five sequence insertions ranging from seven to 56 amino acid residues are
found, the largest one having the D/N/K-rich repeat. Surprisingly, PfORC5 has
been demonstrated to have ATPase activity, i.e. not only binding but also
hydrolysis of ATP.9 Chimeric ORC5 (composed of the N-terminus of ScORC5
and the C-terminus of PfORC5), but not full-length PfORC5, was shown to be
able to complement an ScORC5-deficient yeast strain, confirming that PfORC5
is a true homologue of ORC5.9 PfORC5 is predominantly expressed in tro-
phozoite and early schizont stages, and in sexual stages.9,14 It was reported that
PfORC5 co-immunoprecipitates with PfPCNA1 (see Section 13.3.4) from
mixed trophozoite extract, and co-localises with PfPCNA1 replication foci in
vivo during early-to-mid replicating trophozoite stages, with PfORC5 and
PfPCNA1 starting to dissociate from each other during further growth pro-
gression and finally separating completely during late schizont stages.9 PfORC5
was also shown to co-localise with PfORC1 foci from mid-trophozoite to mid-
schizont stages until PfORC1 was completely diminished in late schizont
stages.9
13.2.2 PfCDC6
CDC6 is an ATP-binding protein that plays a crucial role in the assembly of
the pre-replication complex (pre-RC) (see Chapters 1 and 2). CDC6 requires
ORC to associate with chromatin and is in turn required for MCM2-7
chromatin association. The CDC6 homologue was thought to be absent in
P. falciparum;10,11 however, our extensive bioinformatics studies reveal that a
gene located on chromosome 5 does encode a PfCDC6-like protein in the
parasite. Like PfORC1 (Figure 13.2A), there are six blocks in the central region
of PfCDC6 showing strong similarity with members of the ORC1/CDC6/
Cdc18 family including the Walker A (GPSGQGKT) and B (DELD) motifs,12
suggestive of an ATPase activity of PfCDC6. PfCDC6 contains the conserved
region corresponding to domains I and II of archaeal Cdc6 and can presum-
ably form a two-lobed, cashew-shaped molecule as does archaeal Cdc6.20
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Interestingly, between the first two conserved blocks, there is an amino acid
insertion of more than 50 residues, which may present a target for development
of novel anti-malarial drugs. PfCDC6 seemed to be predominantly expressed in
gametocyte but weakly in late trophozoite stages.14,19
13.2.3 PfCDT1
CDT1 protein, like CDC6, is required to load the MCM helicase at the repli-
cation origin to form the licensed pre-RC (see Chapter 1). Our bioinformatics
analysis reveals that there is a putative PfCDT1 protein in the parasite genome.
PfCDT1 shares up to 21% identity and 43% similarity with other members of
the Cdt1 family between residues 544–700, although two short helices (H1 and
H2) and loop L1 in mouse Cdt1 that contact with the N-terminal part of the
geminin dimer are absent in PfCDT1. Perhaps this is less surprising in light
of the absence of any identifiable geminin-like protein in the parasite genome
(as is also the case in yeast; geminin may be a feature of metazoan replication
control). Near the C-terminus is a leucine zipper motif (LX6LX6LX6L, posi-
tions 921–950), suggesting that PfCDT1 may possess DNA-binding activity.
It will be interesting to investigate whether PfCDT1 is required in replication
initiation as would be predicted from its similarity to Cdt1 from other species.
Consistent with a role in DNA replication, PfCDT1 is transcribed in both
asexual (trophozoite and schizont) and sexual (gametocyte) stages.14
13.2.4 PfMCM
In eukaryotes, the MCM complex is composed of six conserved proteins
(MCM2-7) and is recruited to replication origins by Cdc6 and Cdt1 to function
as the replicative DNA helicase (see Chapter 3). Although PfMCM4 was
the first malarial MCM member isolated from the parasite,21 all six MCMs
(PfMCM2-7) have now been identified in the parasite, the smallest being
PfMCM5 (758 amino acid residues, predicted molecular mass 85.7 kDa) and
the largest being PfMCM4 (1005 residues with predicted molecular mass 115
kDa) (Table 13.1). Although it has been reported that none of the PfMCM
genes contain introns,11 we have found that four out of six (i.e. PfMCM2, 3, 5
and 7) contain between one and three introns (Li et al., unpublished data).
Comparisons of the PfMCM sequences reveal that the central region of
approximately 200 amino acids is conserved in all six members, including
the Walker A and B motifs and the MCM signature motif (IDEFDKM). In
addition, a zinc finger motif (CX2CX18CX2"4C), characteristic of DNA-bind-
ing domains, is present in the N-terminal region of four PfMCMs (PfMCM2, 4,
6 and 7), as would be expected for these four members, although there is a
slight variation for the motif in PfMCM2 (CX2CX21CX2C) and in PfMCM4
(CX13CX18CX2C). Moreover, all PfMCMs contain various unique sequence
insertions ranging from five to 84 residues compared with members of each
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MCM family in other species. For example, PfMCM4 has five unique amino
acid insertions with sizes from five to 84 residues located in different places in
the sequence21 (see Figure 13.3).
Co-immunoprecipitation demonstrated that PfMCM2, 6, and 7 are present
in a protein complex; among them, PfMCM6 is the only protein that is tightly
associated with chromatin, suggesting that PfMCM6 may directly interact with
chromatin, while other PfMCMs probably associate via protein-protein inter-
actions.11 PfMCM2-6 all appear to be transcribed during trophozoite, schizont
and gametocyte stages14,19,21 while some (i.e. PfMCM3, 4, 5 and 7) are also
expressed in sporozoites.14 At the protein level, PfMCM2 has been demon-
strated to peak in late schizont/segmented schizont stages, PfMCM6 in late
trophozoite and schizont/segmented schizont stages, and PfMCM7 in schizont/
segmented schizont stages.11 Immunofluorescent staining revealed the
PfMCM4 protein in trophozoite, schizont and gametocyte stages.13 In other
eukaryotic systems, the MCM complex is regulated at replication initiation by
phosphorylation by cyclin-dependent kinases (e.g. Clb5/6-CDK1 in yeast,
together with Cdc7-Dbf4). Moreover, association of DNA pol a-primase at the
pre-initiation complex is usually mediated by Cdc45.22–24 However, despite
extensive analysis, we have been unable to identify Cdc45 and Dbf4-Cdc7
(DDK) homologues in the parasite genome.
In this context, it is interesting to note that structural changes in yeast
MCM5 can remove the need for Dbf4-kinase activation of the MCM complex
at initiation.25 It will therefore be interesting to see whether the PfMCM
complex can similarly be activated without the need for Cdc7-Dbf4-dependent
phosphorylation.
13.2.5 PfMCM8 and PfMCM9
MCM8 and MCM9 proteins are conserved in a diverse array of eukaryotes but
are lacking in most fungi, Caenorhabditis elegans and Giardia lamblia, and thus
were originally thought to be vertebrate-specific proteins26 (see also Chapter 3).
However, we have identified MCM8 and MCM9 homologues in the malarial
parasite, and found that they are very similar to even their human orthologues
(Li et al., unpublished data): PfMCM8 shares 34% identity and 55% similarity
with human hMCM8 in two separate regions and contains all MCM2-7 family
Figure 13.3 Sequence comparisons between P. falciparum and human MCM4. The
sequences were aligned with the CLUSTAL W (1.85)71,72 using data
derived from GenBank/EMBL/DDJB database accession numbers:
P. falciparum PfMCM4, AF083323; human MCM4 (aka CDC21),
P33991; and mouse MCM4, P49717. Inserts A–E are labelled and
underlined at the bottom of sequence. The zinc-finger motif
(CXnCX18CX2C) is highlighted in grey and the Walker A and B motifs are
highlighted and indicated at the bottom of sequence. Note that murine
MCM4 is included to demonstrate the very high degree of conservation of
MCM4 in mammals.
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10 20 30 40 50 60 70 80
----:----|----:----|----:----|----:----|----:----|----:----|----:----|----:----|
Consensus MxSPxxxxxRRxSxxxxxxxxxSxxxxxSxSxxxxxxxxxxxxSTxxxxxxxTxxxxxLxxxxxxNxxxSxxxxMxxxxx
MCM4_MOUSE MSSPASTPSRRSSRRGRVTPTQSLRSEESRSSPNRRRRGEDS-STGELLPMPTSPGADLQSPPAQNALFSSPPQMHSLAI
MCM4_HUMAN MSSPASTPSRRGSRRGRATPAQTPRSEDARSSPSQRRRGEDSTSTGELQPMPTSPGVDLQSPAAQDVLFSSPPQMHSSAI
PfMCM4 MGTPRRRLGQQNNNNNSPFALSSSNIFGSNNEIFGSNFMHTPMSSRRTKNSKSFLNSMLNESRYLNQSNAGSQFIKYGHT
90 100 110 120 130 140 150 160
----:----|----:----|----:----|----:----|----:----|----:----|----:----|----:----|
Consensus PLxxxxxxxxxxxxxxxxxExxxxxxxxGxxxxxxxxxxxxxKxLxxxxxxDxxxxxxxxxxDxxxxEQSLxQxLVIxxx
MCM4_MOUSE PLDFDVSSPLTYGTPSSRVEGTPRSGVRGTPVRQRPDLGSARKGLQVDLQSDGAAAE-----DIVPSEQSLGQKLVIWGT
MCM4_HUMAN PLDFDVSSPLTYGTPSSRVEGTPRSGVRGTPVRQRPDLGSAQKGLQVDLQSDGAAAE-----DIVASEQSLGQKLVIWGT
PfMCM4 PLAIRRIKCARADIGDVGREAFMEDEESGRLPHFIDSNLEQIKELFNQFFDEFNITNYSDVLDFTDEDRSISEYILLHRD
Insert A
170 180 190 200 210 220 230 240
----:----|----:----|----:----|----:----|----:----|----:----|----:----|----:----|
Consensus DVxVxxxxxxFQxxLxxFxDxxxKxExxxxNxxxDxxExxxxxxxGxxNIxxxxxxxVNxxHIxxFNKxLYRxLIxYPxE
MCM4_MOUSE DVNVATCKENFQRFLQCFTDPLAKEE---ENVGIDITQPLYMQQLGEINITGEPFLNVNCEHIKSFSKNLYRQLISYPQE
MCM4_HUMAN DVNVAACKENFQRFLQRFIDPLAKEE---ENVGIDITEPLYMQRLGEINVIGEPFLNVNCEHIKSFDKNLYRQLISYPQE
PfMCM4 NLKVYLAYYGWK--MIKFIETGRQNECRLNNTNYEDDDENNENSEGIRNLEHIKSFEIDLTHIFFFNKKLYKLIIEYPSD
250 260 270 280 290 300 310 320
----:----|----:----|----:----|----:----|----:----|----:----|----:----|----:----|
Consensus xIxxxDxxVNxxFxxxxxxxxxxxxxxxxxDRYPxxSxxExxxQVRxFNxxxxxSxRxLxPxxIDxLIxIxGMVIRxSxL
MCM4_MOUSE VIPTFDMAVNEIFF----------------DRYP-DSILEHQIQVRPFNALKTKSMRNLNPEDIDQLITISGMVIRTSQL
MCM4_HUMAN VIPTFDMAVNEIFF----------------DRYP-DSILEHQIQVRPFNALKTKNMRNLNPEDIDQLITISGMVIRTSQL
PfMCM4 CISEIDKIISTKYNSLLALVLEGDTRSSSSDKYPLSSTKQDYCRVRFFNKKHKDTPRKLGPNQIETLVCVKGVIIRCSNI
Insert B
330 340 350 360 370 380 390 400
----:----|----:----|----:----|----:----|----:----|----:----|----:----|----:----|
Consensus IPEMxxAxFQCxxxxxxxxxxxQxCxxxxxxxIxRGxIxEPxxCxxCHxxHSxxLxHNxxxFSxKQMIKLxExxExMxxG
MCM4_MOUSE IPEMQEAFFQC-----------QVCAHTTRVEIDRGRIAEPCSCVHCHTTHSMALIHNRSFFSDKQMIKLQESPEDMPAG
MCM4_HUMAN IPEMQEAFFQC-----------QVCAHTTRVEMDRGRIAEPSVCGRCHTTHSMALIHNRSLFSDKQMIKLQESPEDMPAG
PfMCM4 IPEMTMAAFKCTSKKRIGVNNYEKCNEEVYEHVIQGEVQEPVTCSNCNNKNTFELWHNNCCFSSKQLIKLSEVTEHLKQG
Insert C
410 420 430 440 450 460 470 480
----:----|----:----|----:----|----:----|----:----|----:----|----:----|----:----|
Consensus QTPxTIxLFAHNDLVDxxQPGDxVxVTGIxRAxPIRVNPRxxxxxSVYKTHIDVIHxRKxDxKRLxxxDExxxxxxxxxx
MCM4_MOUSE QTPHTIVLFAHNDLVDKVQPGDRVNVTGIYRAVPIRVNPRVSNVKSVYKTHIDVIHYRKTDAKRLHGLDE----------
MCM4_HUMAN QTPHTVILFAHNDLVDKVQPGDRVNVTGIYRAVPIRVNPRVSNVKSVYKTHIDVIHYRKTDAKRLHGLDE----------
PfMCM4 ETPQSISIYAYDDLIDYTKPGDTVELTGILKASPVRLNPRSRCYNSVHRTYINVIHIKKENKQKMKLTEQNDTANIILKR
490 500 510 520 530 540 550 560
----:----|----:----|----:----|----:----|----:----|----:----|----:----|----:----|
Consensus xxxxxxxxxxxxxxExxxxLFSxKxVExLKELSRxPDIYERLxxALAPSIYxxxDIKKGILxQLFGGTRxxxSxxxxxKF
MCM4_MOUSE --------------EAEQKLFSEKRVKLLKELSRKPDIYERLASALAPSIYEHEDIKKGILLQLFGGTRKDFSHTGRGKF
MCM4_HUMAN --------------EAEQKLFSEKRVELLKELSRKPDIYERLASALAPSIYEHEDIKKGILLQLFGGTRKDFSHTGRGKF
PfMCM4 NEDGTVEENFEKLNEQGNLLFTTEVIQKMEQLSKDPNIYQRLVDSIAPSIYGRGDIKKGLLCQLFGGSK--ITDKYNNKY
Insert D
570 580 590 600 610 620 630 640
----:----|----:----|----:----|----:----|----:----|----:----|----:----|----:----|
Consensus RAEINILLxGDPxTSKSQLLxYVYxLxPRGxYTSGKGSSAVGLTAYVxKDxETRQxVLQTGALVLSDxGICCIDEFDKMN
MCM4_MOUSE RAEINILLCGDPGTSKSQLLQYVYNLVPRGQYTSGKGSSAVGLTAYVMKDPETRQLVLQTGALVLSDNGICCIDEFDKMN
MCM4_HUMAN RAEINILLCGDPGTSKSQLLQYVYNLVPRGQYTSGKGSSAVGLTAYVMKDPETRQLVLQTGALVLSDNGICCIDEFDKMN
PfMCM4 RSEIHILLRGDPSTAKSQLLHYVHKLSPRGIYTSGKGSSSVGLTAFISKDSETKEYILESGAVVLSDKGICCIDEFDKMD
Walker A Walker B
650 660 670 680 690 700 710 720
----:----|----:----|----:----|----:----|----:----|----:----|----:----|----:----|
Consensus ESxRSVLHEVMEQQTLSIAKAGIIxxLNARTSVLAAANPIxSQWNxxKxxIENIxLPxTLxSRFDLIFLMLDxxDExxDR
MCM4_MOUSE ESTRSVLHEVMEQQTLSIAKAGIICQLNARTSVLAAANPIESQWNPKKTTIENIQLPHTLLSRFDLIFLMLDPQDEAYDR
MCM4_HUMAN ESTRSVLHEVMEQQTLSIAKAGIICQLNARTSVLAAANPIESQWNPKKTTIENIQLPHTLLSRFDLIFLLLDPQDEAYDR
PfMCM4 DSARAILHEVMEQQTVTIAKAGIVATLNARTSILASANPINSRYDKNKAVVENINLPPSLFSRFDLIYLVIDQANEDEDR
730 740 750 760 770 780 790 800
----:----|----:----|----:----|----:----|----:----|----:----|----:----|----:----|
Consensus RLAxxLxxxYxxSxEQxEEExxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
MCM4_MOUSE RLAHHLVSLYYQSEEQVEEE------------------------------------------------------------
MCM4_HUMAN RLAHHLVALYYQSEEQAEEE------------------------------------------------------------
PfMCM4 KLATVLCKNFSYNPEEEEDEDQEDQEEDEPNYITQQRARKSKGTSRKNERENYYNDGDNDDDDDISNYLNDSNDAQNKRG
Insert E
810 820 830 840 850 860 870 880
----:----|----:----|----:----|----:----|----:----|----:----|----:----|----:----|
Consensus xxxxxxxxxxxxxxxxxxxxxxxxxLDxxxLxxYIAYxxxTxxPxLSxEAxQxLIExYVxMRxxxxSRxxxSAxPRQLEx
MCM4_MOUSE ------------------------FLDMAVLKDYIAYAHSTIMPRLSEEASQALIEAYVNMRKIGSSRGMVSAYPRQLES
MCM4_HUMAN ------------------------LLDMAVLKDYIAYAHSTIMPRLSEEASQALIEAYVDMRKIGSSRGMVSAYPRQLES
PfMCM4 SWANVNISYDEYNNSSNKKTSKNYLIDSNTLALYIAYCRITCNPIISLESKKIIIEEYIKMRCKEGTKS-PTASPRQLEG
890 900 910 920 930 940 950 960
----:----|----:----|----:----|----:----|----:----|----:----|----:----|----:----|
Consensus LIRLAEAxAKVRxxxxVxxxDxxEAxRLxxxAxxQSxxDPxTGxVDxxxLxxGxSAxxRKRxExLxExLxxxILxKxxTx
MCM4_MOUSE LIRLAEAHAKVRFSNKVEAIDVEEAKRLHREALKQSATDPRTGIVDISILTTGMSATSRKRKEELAEALRKLILSKGKTP
MCM4_HUMAN LIRLAEAHAKVRLSNKVEAIDVEEAKRLHREALKQSATDPRTGIVDISILTTGMSATSRKRKEELAEALKKLILSKGKTP
PfMCM4 LVRLSQSLAKMKLKRVVSPEEANEAVRLMNIATFQSLIDPLSGRIDFDQVNLGQTSQHKKKSDLIKDIIMNALVLKNMTK
970 980 990 1000 1010 1020 1030 1040
----:----|----:----|----:----|----:----|----:----|----:----|----:----|----:----|
Consensus xxxxxxxxExIxxxxQxxxAIxKxxFEEAxxxLxxxxxLTxxxxxVxxxx
MCM4_MOUSE ALKYQQLFEDIRG--QSDTAITKDMFEEALRALADDDFLTVTGKTVRLL-
MCM4_HUMAN ALKYQQLFEDIRG--QSDIAITKDMFEEALRALADDDFLTVTGKTVRLL-
PfMCM4 DELLTHCHETIMNDPQHTTSMDRKSFEEAFYDLEKSQEITRLCSGLYKKK
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domains including the Walker A (GDPGLGKS) and Walker B (CIDELDKI)
motifs as well as the conserved zinc finger motif (CX2CX18CX4C). However,
compared with hMCM8, PfMCM8 has three sequence insertions of six, 26 and
186 amino acid residues, respectively. In addition, near the N-terminus, there
are six copies of a hexameric GNKN(Y)G(E)K repeat. PfMCM8 appears to be
transcribed in trophozoite and schizont stages, but at slightly higher levels in
the sporozoite.14
PfMCM9 is the largest of the PfMCM family members, comprising 1465
amino acid residues with a predicted molecular mass of 171.2 kDa. The
PfMCM9 gene is transcribed in late trophozoite and early schizont stages, and
in sexual stages.14,19 In five separate regions between residues 412–1400,
PfMCM9 shares 37% identity and 57% similarity with human and mouse
MCM9, including the Walker A (GDPGTGKS) and B (CIDEFCLM) motifs
as well as the full MCM2-7 family domain. However, there are a number
of unique amino acid insertions in PfMCM9. Compared with other members
in the MCM9 family, PfMCM9 lacks the C-terminal region but has the large
N-terminal extension. In addition, there are two types of amino acid sequence
repeats, i.e. 13 copies of NN(Y)D(G)DNK at positions 149–226 and 12 copies
of INV(G)D(N)D(N) at positions 721–780. How these repeats arose and
whether they serve a function in parasite replication remain open questions.
13.3 Replication Elongation Proteins
13.3.1 PfRPA
Replication protein A (RPA) functions as a heterotrimeric complex that stabi-
lises single-stranded DNA (ssDNA), and coordinates the sequential assembly
and disassembly of DNA processing proteins on ssDNA during replication, and
also during repair and transcription.27,28 The largest subunit, RPA1 (hRPA70 in
humans), contains the primary ssDNA-binding activity, while the two smaller
subunits, RPA2 (hRPA32) and RPA3 (hRPA14), stabilise the complex and
mediate interactions with replication and repair machinery,28 (see Chapter 6).
In P. falciparum, we have identified five putative subunits, i.e. two RPA1-type
proteins (PfRPA1 and PfRPA10), two RPA2-like molecules (PfRPA2 and
PfRPA20), and one RPA3 protein (PfRPA3) (Li et al., unpublished data).
PfRPA1 was the first malarial RPA to be experimentally identified, through
affinity purification of a 55 kDa factor possessing the major ssDNA-binding
activity in asexual stage extracts.29 Mass spectral analysis of 11 tryptic peptides
demonstrated that the 55 kDa protein is the C-terminal fragment of PfRPA1.
PfRPA1 consists of 1145 amino acids with a predicted mass of 134.1 kDa,
but it shares 30–39.2% identity with other eukaryotic RPA1 family members
only within the C-terminal 466 amino acids. PfRPA1 possesses three ssDNA-
binding domains:30 DBD-A (positions 685–778), DBD-B (817–919) and
DBD-C (958–1134); and a consensus zinc finger motif (CX2C26CX2C,
986-1019) within DBD-C. However, in the N-terminal region of PfRPA1, no
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significant homology to any known protein was identified; this non-conserved
region may provide a suitable target for development of anti-malarial agents.
PfRPA1 appears to be expressed in late trophozoite and schizont stages29 as
well as in sexual (gametocyte) and sporozoite stages.14
The second malarial RPA1, which we term PfRPA10, consists of 484 amino
acids with a calculated molecular mass of 56.1 kDa, and shares 26% identity
and 50% similarity with PfRPA1. Like PfRPA1, PfRPA10 contains the DNA
binding domains DBD-A (10–109), DBD-B (140–247), DBD-C (275–451), and
the zinc finger motif (CX2C28CX2C, 315–350) characteristic of RPA1, but lacks
the N-terminal protein interaction domain. PfRPA10 seems to be expressed in
trophozoite and schizont stages, and in sexual (gametocyte) and in sporozoite
stages.14,19
Two putative malarial RPA2 subunits, PfRPA2 and PfRPA20, consist of 273
and 191 amino acids with calculated masses of 31.6 and 22.3 kDa, respectively,
and share 39% identity and 57% similarity each other in the central region.
Importantly, PfRPA2 and PfRPA20 each contain the consensus DBD-D DNA
binding domain, together with several potential interface sites with RPA1
DBD-C and RPA3, and possible phosphorylation sites in their N-terminal
regions. PfRPA2 seems to be weakly expressed in sporozoite and in early
schizont and gametocyte stages, while PfRPA20 is expressed in gametocyte and
early trophozoite stages.14
The smallest malarial subunit, PfRPA3, consists of 135 amino acids with a
predicted molecular mass of 15.4 kDa, and contains several putative interface
sites with RPA2 DBD-D and RPA1 DBD-C. PfRPA3 appears to be expressed
very weakly in gametocytes.14
13.3.2 DNA Polymerases
DNA polymerases a, d and e are the three established polymerases responsible
for the bulk of DNA replication (see Chapter 4) that are sensitive to aphidicolin
but insensitive to dideoxynucleotide analogues. There have been several reports
on stage-dependent, aphidicolin-sensitive and aphidicolin-resistant DNA
polymerase activities in the asexual stage extracts of P. falciparum.31–33 DNA
polymerase activity was undetectable in ring-form extracts, but increased
in trophozoites and peaked in schizonts. Seven DNA polymerase activities
have been identified and partially purified from P. berghei, five of which are
aphidicolin-sensitive, while two are resistant.34
13.3.2.1 PfPola
The pol a-primase complex is responsible for making a chimeric RNA–DNA
primer of B40 nucleotides for initiating DNA synthesis, and is composed
of a large catalytic subunit (Pola/p180), an intermediate B subunit (p70) and
two small subunits (PriL/p55 and PriS/p48).35 The largest subunit possesses
the polymerase catalytic activity, while the two small subunits, PriS and PriL,
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together function as the core primase for creating an RNA primer of 6–15
nucleotides.36 The malarial Pola catalytic subunit (PfPola), B subunit
(PfPolaB) and two small primase subunits (PfPriS and PfPriL) have been found
in the parasite genome.
PfPola shares 14–17% overall identity only with other members of the Pola
family but contains all seven motifs I–VII conserved in DNA polymerases,
together with four of five Pola-specific motifs (A–E). However, PfPola has a
number of unique features. Firstly, motif A, present in the human counterpart,
is absent in PfPola. Secondly, in motif D, a highly conserved glycine (residue
G493 in ScPola), implicated in the interaction with DNA primase in yeast, is
replaced by Leu in P. falciparum. Thirdly, there are at least six sequence
insertions with sizes ranged from 10 to 91 amino acids interspersed between the
polymerase-specific motifs, two of which contain repeated sequences. Insertion
2 has seven degenerate copies of repeat QQSVVS, while insertion 4 has four
copies of the degenerate repeat KNIHSD. Oddly, the QQSVVS motif is shared
with an RNA-directed RNA polymerase from bovine viral diarrhoea virus
(Swissprot accession P19711). Fourthly, there are four Asn-rich tracts, three in
the N-terminal region and one in the C-terminal region. Finally, PfPola has a
novel C-terminal extension of 98 residues compared with the human counter-
part. PfPola is transcribed in asexual and sexual stages.37
PfPolaB shares 24% identity and 48% similarity with its human counterpart
in the region of 148–514. However, PfPolaB contains two unique sequence
insertions with nine and 12 residues, respectively, compared with the human
orthologue. PfPolaB seems to be expressed in asexual and sexual (gametocyte)
stages, and the sporozoite stage.14,19
Primase in the parasite is encoded by two genes, PfPriL and PfPriS. PfPriL
shares 33% identity and 53% similarity with its human orthologue, including
a putative iron–sulfur cluster coordinated by four conserved cysteine residues
(C362, 438, 456 and 496) that contributes to enzymatic activity of the core
primase.38
PfPriS, encoded by a gene containing 15 introns, displays 36% identity and
53% similarity with its human counterpart. It contains all five domains (I–V)
conserved in eukaryotic primase small subunits, including three catalytic
aspartates (D130, 132 and 347) and the consensus sequence SGXRG (residues
181–185) involved in nucleotide binding. Additional conserved regions, termed
Ia, VI and VII, are found in mammalian and yeast homologues.39 However,
PfPriS has three unique sequence insertions, two flanking domain Ia and one
before domain V. Primase activity has been confirmed for recombinant PfPriS
expressed in insect cells.39 Both PfPriL and PfPriS appear to be expressed in
trophozoites, schizonts, gametocytes and sporozoites.14
13.3.2.2 PfPold
DNA polymerase d functions as a heterotetramer in fission yeast and mammals
(see Chapter 4), and consists of a tightly associated dimer of a large catalytic
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subunit (p125) and a small subunit (p50), which is associated with two other
subunits (p68 and p12). However, in budding yeast, only three subunits have
been identified.40 In P. falciparum, two subunits, the large catalytic subunit
(PfPold) and the small regulatory subunit (PfPoldS) have been identified.
PfPold shares 46% identity and 67% similarity with Schizosaccharomyces
pombe Pold between amino acids 97–1013.41,42 PfPold contains all seven major
motifs (I–VII) used to identify DNA polymerases in a correct spatial order, five
additional regions (d1-5) conserved in members of the Pold family, and two
putative zinc finger motifs (CX2CX9CX2C, 1003-1019; CX2CX9CX4C, 1049-
1067). In addition, PfPold has the 30–50 exonuclease domain (residues 126–471)
responsible for conferring proofreading activity, and retains several conserved
residues (D308, I309, E310, Y390, D396 and D509) that presumably form the
exonuclease catalytic site. PfPold is transcribed in asexual (trophozoite
and schizont) and sexual (gametocyte) stages41,42 as well as in sporozoites.14
Western blotting analysis revealed that PfPold protein is expressed in tropho-
zoite and schizont stages, but not in the ring stage.43
PfPoldS is slightly less conserved, showing up to 33% identity and 56%
similarity with other members of the Pold2 family. PfPoldS seems to be tran-
scribed in asexual (trophozoite, schizont), sexual (gametocyte) and sporozoite
stages.14
13.3.2.3 PfPole
Pol e comprises four different subunits in vertebrates (Pole A–D) and budding
yeast (Pol2/256kDa, Dpb2/79kDa, Dpb3/23kDa, and Dpb4/22kDa).40 The DNA
polymerase and 30–50 exonuclease of polymerase e reside in the largest subunit. In
P. falciparum, genes encoding both the catalytic subunit (PfPole) and the second
largest subunit (PfPoleB) have been found in the parasite genome. PfPole displays
significant homology to its human counterpart in four different regions:
# 30% identity and 54% similarity in the region of 27–175;
# 37% identity and 57% similarity in the region of 259–1406;
# 28% identity and 49% similarity in the region of 1729–1841;
# 25% identity and 46% similarity in the region of 2714–2899.
PfPole contains all seven ordered motifs (I–VII) conserved in DNA poly-
merases in the N-terminal region, the exonuclease domain in the region of
337–635 including several conserved residues (D344, I345, E346, Y433, D439
and D533) that form the exonuclease catalytic site, plus two putative zinc finger
motifs (CX2CX26CX2C, 2782-2815; CX2CX11CXC, 2845-2863) conserved in
the Pole family at the C-terminal side. In addition, a putative PCNA-binding
motif, QKKITSFF (1312-1319), is found in the middle part of PfPole, sug-
gestive of an interaction with PfPCNA. It is noted that PfPole also possesses
numerous sequence insertions compared with its human counterpart; such
additional sequences may prove useful in directed drug design.
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PfPoleB shares 23% identity and 44% similarity with human PoleB in the
region of 168–575. PfPoleB appears to be expressed in trophozoite and schizont
stages.14,19
13.3.3 PfRFC
RFC consists of five non-identical subunits (RFC1–5) and is a DNA-dependent
ATPase that functions as the clamp loader for PCNA (see Chapters 2 and 3) to
confer processivity on DNA Pol d and e. We have identified all five subunits
in the parasite and our Northern blot hybridisation shows that PfRFC1-5 are
all expressed in asexual and sexual stages (J-L. Li and A. Goldsmith,
unpublished data).
Each PfRFC subunit contains three domains (domains I–III) and the pri-
mary sequence of these domains is homologous among the five subunits; only
PfRFC1, the large subunit, has additional N- and C-terminal regions. There is
an overall similarity between the parasite PfRFC and corresponding ortholo-
gues in most other eukaryotes. All RFC boxes (I–VIII) occur in PfRFC, ranged
from the N-terminus to the C-terminus.
# Box I is present only in PfRFC1 and consists of about 95 amino acids
from positions 185–280. This region shows homology to the DNA ligase
homology domain and BRCT, the BRCA1 C-terminus domain.
# Box II, at the N-terminus of PfRFC2-5, shows the WV(I,L)E-
KYR(S)PXXL(I) consensus sequence.
# Box III, contains the phosphate-binding motif (P-loop) with the consensus
sequence GXXGXGKT(S). It is notable that a classic GKT(S) sequence
in the consensus P-loop is replaced by GKK in both human hRFC38 and
yeast ScRFC5; however, PfRFC5 retains the motif (GKS) in the P-loop.
# Box IVcontains the L(I)EL(F)NASD sequence although a motif variation
(LELQCFE) occurs in PfRFC5.
# Box V has the DEA(V)D motif, which for PfRFC5 is replaced by KDAE,
suggesting that PfRFC5 might not be able to hydrolyse ATP.
# Box VI is different in the small and the large PfRFC subunits, as would be
expected.
# Box VIa, only present in PfRFC1, has the consensus sequence of
GMSsGDKGGstaI while box VIb, present in the PfRFC2-5 subunits,
shows xM(L)T(S)xxAQxxL(M)RRI(t)M(I/L)E.
# Box VII, the arginine finger motif (SRC), is conserved in all small subunits
(PfRFC2-5) but only the cysteine is present in PfRFC1, as would be
expected for members of the RFC1 family.
# Box VIII has the consensus sequence GDL(M/I)RxxA(M/I)L(V)xxLQ,
which for PfRFC5 is replaced by THGRNLRKVI.
These sequence characteristics suggest that all PfRFC subunits may bind
ATP (via Walker A boxes), but that only PfRFC2-4 may effectively hydrolyse
the bound ATP by virtue of their Walker B boxes.
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13.3.4 PfPCNA
Proliferating cell nuclear antigen (PCNA) functions as a DNA sliding clamp
that tethers the replicative DNA polymerases to the template, and also interacts
with and regulates the activities of numerous proteins involved in DNA and
chromatin processing during DNA synthesis (see Chapter 3). In yeast and
mammals, only one form of PCNA has been found; this associates into a
homotrimer with pseudo-sixfold symmetry.44,45 By contrast, two different
PCNAs have been described in the malarial parasite46–48 (note that three dif-
ferent forms with subtly different interaction profiles have been characterised
in Crenarchaea—see Chapter 12).
PfPCNA1 shares 29% identity and 53% similarity with PfPCNA2.
PfPCNA1 and 2 are not only expressed in asexual trophozoite and schizont
stages,43,47,48 but also in the sexual gametocyte stage,47 consistent with a role in
rapidly proliferating cells. Both PfPCNA1 and PfPCNA2 contain all conserved
motifs of members of the PCNA family, including the potential DNA-binding
and protein interaction domains. PfPCNA2 may form a homotrimeric struc-
ture and PfPCNA1 may multimerise, but whether it forms dimers or trimers is
unclear.47,48
Compared with human hPCNA, both PfPCNAs have a unique sequence
insertion (PfPCNA1 with nine amino acid residues and PfPCNA2 with
seven residues) just before the I2 motif. In addition, PfPCNA2 contains a
second insertion with four amino acid residues located just before the
bH1 region. We have conducted structural modelling of PfPCNA2 based
on the published crystal structure for human PCNA,44 and as shown in
Figure 13.4, the additional regions present in PfPCNA2 but absent in hPCNA
(white arrows in Figure 13.4) may be solvent-exposed and thus accessible to
drugs.
13.3.5 PfFen1
Fen1, a structure-specific 50 endo/exonuclease, cleaves a 50-unannealed flap
and degrades nucleotides from a nick or a gap on dsDNA. It plays a key role in
the removal of RNA primers during Okazaki fragment maturation in lagging
strand DNA synthesis (see Chapter 5), long-patch base excision repair and
maintaining genome stability.
The malarial Fen1, PfFen1, shares up to 54% identity and 72% similarity
with other members of the Fen1 family and consists of five regions. The N and I
regions, like other members in the Fen1 family, constitute the nuclease core
domain (residues 1–345) which contains the helical clamp region (residues
89–136), the helix-three turn-helix motif (residues 234–266), and seven critical
acidic residues that cluster to form two active sites. By analogy to human
FEN1, four of the acidic amino acids in PfFen1 (D34, D88, E160 and E162) are
predicted to form the first metal ion-binding site, and three others (D181, D183
and D246) are likely to be involved in forming the second metal ion-binding
site. The C region, located internally, contains the conserved PCNA-binding
motif (QRRLDNFF, 350–357) that in fact forms a part of the bA–aA–bB
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structure, the main interacting interface with PCNA.49,50 PfFen1 can generate
a nicked DNA substrate that can be ligated by PfLigI.51,52 PfFen1 seems to
be transcribed in both asexual and sexual stages (J-L. Li, unpublished data).
Western blot analysis of parasite lysates from the erythrocytic stages revealed
that PfFen1 protein is present in all asexual stages.51
The R region, unique to PfFen1, has the DdeKXX hexamer repeated 12
times (residues 421–492). The E region (residues 493–672), the unique large-
extended C-terminal segment, is present in a natively disordered state with no
discernible secondary structure but possesses a putative NLS motif (residues
645–667). Although such unique extensions may appear to be prime targets for
designing agents to inhibit malarial DNA replication without impacting on the
function of essential host enzymes, functional analysis is critical in determining
target validity. For example, the R and E regions of PfFen1 negatively influence
Figure 13.4 Predicted structural model of PfPCNA2 monomer. Homology modelling
of PfPCNA2 (green) was conducted using SWISS-MODEL73,74 using the
coordinates obtained for yeast PCNA44 (PDB accession number 1PLR)
as a template, and superimposed on human PCNA (red in figure) using
MacPyMOL (http://delsci.com/macpymol/). The additional regions
present in PfPCNA2 but absent in hPCNA are highlighted by white
arrows.
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the enzyme’s activities, since a PfFen1 C-terminal truncation consisting of
about 400 amino acids and lacking the R and E regions possesses endonuclease
and exonuclease activities 300-fold and 30-fold higher than full-length PfFen1,
respectively.51 Thus, these domains serve a regulatory role and their disruption
may promote rather than block parasite DNA replication.
13.3.6 PfRNase H
RNase H specifically degrades the RNA moiety in RNA–DNA hybrids and
plays an important role in DNA replication by removal of the RNA primer of
Okazaki fragments (see Chapter 5). There are two major types of RNase H:
RNase H1 is the smaller enzyme with major activity in prokaryotes, while
RNase H2 is the RNase H large subunit which is most abundant in eukaryotes
and archaea.53
Bioinformatics investigations failed to detect any RNase H1 candidate in the
parasite genome (Li et al., unpublished data), suggesting that RNase H1 might
not be conserved in P. falciparum. However, a malarial orthologue of RNase
H2, PfRNase H2, has been found in the parasite genome. PfRNase H2 is highly
similar to the human RNase H large subunit, sharing 51% identity and 69%
similarity; it retains all the conserved domains, including the active site triad
residues (D22, D130 and D158) and the nearby serine (S168) and glutamate
(E23) discovered in the archaeal orthologue.53 An effort to define the functional
capacity of PfRNase H2 is urgently needed.
13.3.7 PfLigase I
DNA ligase I constitutes the primary ligase utilised in DNA replication and
plays an essential role in the joining of Okazaki fragments and nick sealing. The
malarial DNA ligase I, PfLigI, shares 30% overall identity with human DNA
ligase I, with even greater homology (60% identity) in the C-terminal region.
PfLigI retains all of the conserved domains common to the ATP-dependent
DNA ligase family, including important residues from motifs I–V that con-
stitute the nucleotide binding pocket and motif VI which, together with motifs
I–V, comprises the catalytic core of DNA ligase molecules.
In addition, PfLigI contains a bipartite nuclear localisation motif (residues
100–117), suggesting that PfLigI may be a nuclear protein. However, a unique
apicoplast signal sequence, consisting of a signal peptide and a transit peptide,
occurs in the N-terminus of PfLigI instead of the PCNA binding domain that
normally exists in mammalian counterparts, suggesting that PfLigI might
also be transported into apicoplasts (see Section 13.4.1). In addition, in the
conserved region there is a sequence insertion consisting of about 100 amino
acids compared with mammalian counterparts. PfLigI protein appears to be
expressed in the asexual schizont stage.52 Recombinant PfLigI expressed in
HEK293 cells catalysed phosphodiester bond formation on a singly nicked
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DNA substrate in an ATP-dependent manner, and joined RNA-DNA sub-
strates only when the RNA sequence was upstream of the nick.52
13.4 Potential Targets for Novel Drug Development
P. falciparum contains most of the essential DNA replication components that
are conserved in eukaryotes, suggestive of a similar core replication machinery
of the parasite to that of the human host. However, the parasite seems to lack a
number of core replication proteins including ORC3, ORC6, Cdc45, Dbf4-
Cdc7, geminin and DNA2 helicase, suggestive of some differences in replication
and regulatory pathways between the parasite and the human host, thereby
presenting excellent targets for development of novel anti-malarial drugs.
13.4.1 Targeting Unique Replication Pathways: Apicoplast DNA
Replication
The apicoplast, a chloroplast-like plastid present in P. falciparum and absent in
humans, is no longer photosynthetic, but like chloroplasts, it contains its own
genome and this is essential for parasite survival.54 Apicoplast DNA replication
is dependent on nuclear-encoded apicoplast-targeted proteins (Table 13.3).
DNA gyrase, a typical type II topisomerase that can introduce negative
supercoils in DNA, is required for parasite apicoplast DNA replication.54,55
The malarial gyrase A and gyrase B, PfGyrA and PfGyrB, are encoded in the
nucleus and then transported into the apicoplast. PfGyrB contains strong
intrinsic ATPase activity and, together with the N-terminal domain of PfGyrA,
can efficiently cleave supercoiled DNA.56,57 The fluoroquinolone antibiotic,
ciprofloxacin, that targets bacterial DNA gyrase, has been demonstrated to
inhibit apicoplast DNA replication and growth of the parasite in vitro.8,58,59
Novobiocin, a specific inhibitor of bacterial GyrB, has been shown to inhibit
the ATPase activity of PfGyrB and caused parasite death in culture.57,60 Thus,
PfGyrA and PfGyrB have become attractive targets for use of existing anti-
microbials and for development of novel anti-malarial therapeutics.
PfPOM1, known as P. falciparum plastidic DNA replication/repair enzyme
complex (PfPREX), contains multiple domains with DNA primase, DNA
helicase, DNA polymerase and 30–50 exonuclease activities. The N-terminal
sequence has been demonstrated to direct PfPOM1 to the apicoplast, sug-
gesting that PfPOM1 may have an important role in apicoplast DNA repli-
cation.61 As the polymerase and primase subunits of PfPOM1 have no direct
orthologues in human host cells, PfPOM1 presents a perfect target for new
drug development.
13.4.2 Targeting Unique Protein Sequences
The sequences of malarial replication proteins exhibit high homology to their
human counterparts, but also contain a number of unique features such as large
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N- or C-terminal extensions, numerous sequence insertions within highly
conserved regions, and various amino acid sequence repeats. These unique
properties of the replication proteins offer potentially ideal targets for new drug
therapy. In particular, the extra regions in PfPCNA, and the 12 repeats in the R
region of PfFen1 pose very exciting potential targets, since high resolution
crystallographic data exist on human Fen1–PCNA complexes49 (see also
Figure 3.8), which can be used to model similarities and differences in the
protein folds and interactions. Moreover, the genes encoding these malarial
proteins have been cloned and recombinant protein expressed and assayed
in vitro.46–48,51 Relatively simple in vitro assays for Fen1 nuclease activity51 and
PCNA binding already exist,48,50 both of which should be adaptable to high
throughout methodologies, to allow rapid screening of compounds that spe-
cifically and selectively inhibit malarial but not human Fen1. Given more
investment in the field of malarial research, the identification and character-
isation of Plasmodium replication components should provide a veritable gold
mine of ‘druggable’ targets.
13.5 Concluding Remarks
With the completion of the P. falciparum genome sequencing project,62,63 our
knowledge of the DNA replication machinery in the human malarial parasite
has developed rapidly in the past decade. The parasite contains most DNA
replication components conserved in eukaryotes. Nearly every replication
protein described in P. falciparum has a close orthologue in other malarial
species such as P. vivax, P. knowlesi, P. yoelii, P. berghei, and P. chabaudi.64–66
However, some differences between P. falciparum and other eukaryotes (par-
ticularly humans) have been exploited, particularly at the replication initiation
phase. Based on protein sequence comparisons, many proteins that are abso-
lutely essential for eukaryotic DNA replication cannot be found in the parasite
genome. In addition, a large proportion of replication proteins of the parasite
display unique and interesting features such as terminal sequence extensions,
amino acid sequence insertions and sequence repeats. These attractive char-
acteristics present ideal potential targets for development of novel anti-malarial
drugs.
Unfortunately, the majority of DNA replication components of the parasite
are only at this stage ‘predicted proteins’, being revealed from the parasite
genome using data-mining bioinformatics approaches. It has been shown that
approximately 24% of the parasite genes in current databases were predicted
incorrectly, including one or more additional introns found in some so-called
‘intron-free’ genes, different sizes and locations of introns in numerous pre-
dicted ‘intron-containing’ genes, and alternative splicings for many genes
available in current databases.67 Therefore it is essential to verify amino acid
sequences and real identities of the replication proteins experimentally in the
near future.
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The challenges now are to express replication proteins in heterologous
systems and to purify sufficient amounts of the recombinant proteins for more
detailed biochemical and three-dimensional structural studies. In addition, to
reconstitute a functional malarial replication system in vitro will greatly facil-
itate our understanding of the replication mechanisms in detail, and permit
large-scale screening of natural product and chemical compound libraries for
development of new anti-malarial drugs.
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